menu

QuintilesIMS Blog

Fresh ideas and insights from our experts around the globe

distribution
Brazilians flock to pharmacies: How healthcare companies can bolster sales by embracing this shifting shopper trend
Filtered by 'Endocrinology/Diabetes' ×
Barbara Gillespie
A follow-up report on the CardioVascular Clinical Trialists Forum, and the opportunities to enhance collaboration between cardiologists, endocrinologists, and nephrologists for the benefit of patients with chronic kidney disease.
Read More
Alan Frederickson
How wearable glucose monitoring devices could change the way diabetes trials are conducted.
Read More
Rick Turner
The number of children diagnosed with pediatric type 1 diabetes continues to grow across the globe. In response, throughout the last two decades new insulins and devices have been developed, tested, and approved for use in children. However, the current reality is that most children and adolescents do not reach the targets for metabolic control set by organizations such as the International Society for Pediatric and Adolescent Diabetes and the American Diabetes Association . One complicating factor is that we cannot approach diabetes drug development among children the same way we do for adults. In the world of medicine, children are not simply ‘little adults.’ For example, pediatric patients may metabolize a drug differently than adults and they may experience side effects not...
Read More
Barbara Klimas
Saturday, November 14 was World Diabetes Day, an annual event designed to bring attention to the devastating impact diabetes has worldwide – and the efforts being made to fight this disease. By 2040, almost 642 million will be living with diabetes , many of them children. And the biopharma industry has been working relentlessly to develop new tools and treatments to improve the lives of these patients. One of the most innovative solutions to emerge from these efforts recently is continuous glucose monitoring (GCMCGM). Anyone who has diabetes or is close to someone who does, knows that one of the greatest frustrations of the treatment for this disease are the constant fingersticks to monitor blood glucose levels. CGMs have the potential to reduce the number of fingersticks a person...
Read More
Helena Zhang
Q. How fast is diabetes increasing in China and why? Almost 12 percent (11.6%) of China’s adults have diabetes and more than half (50.1%) have pre-diabetes . That represents 114 million and 493 million people respectively. Changes in lifestyle, (i.e., diet, reduced physical activity, urbanization, etc.), plus pollution are all contributing factors to this increase.> The projected cost of diabetes treatment for Western Pacific patients (predominantly Chinese) in the year of 2030 is estimated to reach USD$60 billion , mainly for the treatment of diabetic complications and end-stage diseases. Recent research paints this picture of diabetes patients in China: It’s hard to find a patient with type 1 diabetes in China who had lived with their disease for 30 years or more. ...
Read More
Susan Sawyer
Tomorrow, November 14, is World Diabetes Day, a day to acknowledge diabetes patients and the great strides we are making across the health care industry to help people prevent and treat this life-long disease. One way we are working to develop and deliver better treatments to patients faster is by improving the way we recruit and support patients throughout clinical trials. This is where Clinical Trial Educators (CTEs) come in. CTEs are typically registered nurses who are specifically chosen for trials because they specialize in a specific disease category and understand the unique needs of patients and their healthcare providers in the clinical trial environment. They can play a key role in ensuring patients feel like a valued part of the trial process, and that all of their needs...
Read More
EricaCaveney
Recruiting for diabetes trials has grown increasingly complicated as more investigators compete to attract a limited population of patients, and face the constant risk of attrition and patients who fail to comply with the treatment protocol. Changes in the regulatory approval process have only added challenges to this process. To meet requirements, including evaluation of cardiovascular risk, investigators are being forced to increase their sample sizes, recruit higher risk (and thus harder to find) patients, and create endpoint-driven, intent-to-treat (ITT) study designs. It can feel overwhelming, however it doesn’t have to be. When investigators follow these planning tips, they can improve their recruiting efforts, reduce attrition, and improve the probability of success. Find...
Read More